(Q34127399)

31 July 2017

1 reference

title

Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy (English)

1 reference

Peer Carsten Tfelt-Hansen

31 July 2017

1 reference

1 reference

1 reference

series ordinal

1

object named as

Tfelt-Hansen P

1 reference

31 July 2017

De Vries P

2

1 reference

31 July 2017

Saxena PR

series ordinal

3

1 reference

31 July 2017

publication date

1 December 2000

1 reference

31 July 2017

1 reference

31 July 2017

volume

60

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

1259-1287

1 reference

Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice

31 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200060060-00003

Subcutaneous sumatriptan during the migraine aura

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200060060-00003

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

21 January 2018

1 reference

12 December 2020

A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group

1 reference

12 December 2020

A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice

1 reference

12 December 2020

A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group

1 reference

12 December 2020

Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors

1 reference

12 December 2020

5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors

1 reference

12 December 2020

Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group

1 reference

12 December 2020

Investigation of the role of 5-HT1B and 5-HT1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses

1 reference

12 December 2020

A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine

1 reference

12 December 2020

Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System

1 reference

12 December 2020

Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers

1 reference

12 December 2020

Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine

1 reference

12 December 2020

A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group

1 reference

12 December 2020

Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study

1 reference

12 December 2020

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

1 reference

12 December 2020

The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.

1 reference

12 December 2020

Sumatriptan in clinical practice: a 2-year review of 453 migraine patients

1 reference

12 December 2020

Sumatriptan for the treatment of migraine attacks--a review of controlled clinical trials

1 reference

12 December 2020

The 5-HT7 receptor: orphan found

1 reference

12 December 2020

Pharmacokinetics and food interaction of MK-462 in healthy males

1 reference

12 December 2020

The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater

1 reference

12 December 2020

Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice.

1 reference

12 December 2020

311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists

1 reference

12 December 2020

5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs

1 reference

12 December 2020

Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies

1 reference

12 December 2020

Naratriptan: biological profile in animal models relevant to migraine

1 reference

12 December 2020

Sumatriptan in acute migraine using a novel cartridge system self-injector. United Kingdom Study Group

1 reference

12 December 2020

Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience

1 reference

12 December 2020

Acute Treatment of Migraine Attacks: Efficacy and Safety of A Nonsteroidal Anti-Inflammatory Drug, Diclofenac-Potassium, in Comparison To Oral Sumatriptan and Placebo

1 reference

12 December 2020

The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation

1 reference

12 December 2020

Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study

1 reference

12 December 2020

The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers

1 reference

12 December 2020

Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan Long-term Study Group

1 reference

12 December 2020

Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries

1 reference

12 December 2020

The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats

1 reference

12 December 2020

Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine

1 reference

12 December 2020

Current concepts of the pathophysiology of migraine

1 reference

12 December 2020

The Clinical Pharmacology, Pharmacokinetics and Metabolism of Sumatriptan

1 reference

12 December 2020

Long-term efficacy of subcutaneous sumatriptan using a novel self-injector

1 reference

12 December 2020

Rizatriptan has central antinociceptive effects against durally evoked responses

1 reference

12 December 2020

Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist

1 reference

12 December 2020

The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group

1 reference

12 December 2020

Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial

1 reference

12 December 2020

Oral sumatriptan for the long-term treatment of migraine: clinical findings

1 reference

12 December 2020

Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache

1 reference

12 December 2020

Comparison of the Efficacy of Zolmitriptan and Sumatriptan: Issues in Migraine Trial Design

1 reference

12 December 2020

Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan

1 reference

12 December 2020

Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group

1 reference

12 December 2020

Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy

1 reference

12 December 2020

Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study

1 reference

12 December 2020

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat

1 reference

12 December 2020

Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group

1 reference

12 December 2020

Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation

1 reference

12 December 2020

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

1 reference

12 December 2020

Long-term experience with sumatriptan in the treatment of migraine

1 reference

12 December 2020

Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks

1 reference

12 December 2020

Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine

1 reference

12 December 2020

Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90.

1 reference

12 December 2020

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

1 reference

12 December 2020

Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).

1 reference

12 December 2020

Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation

1 reference

12 December 2020

Single dose pharmacokinetics of sumatriptan in healthy volunteers

1 reference

12 December 2020

Comparison of the cardiovascular effects of the 5-HT1A receptor agonist flesinoxan with that of 8-OH-DPAT in the rat.

1 reference

12 December 2020

Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: selectively targeting additional sites of action

1 reference

12 December 2020

Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjects

1 reference

12 December 2020

Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration.

1 reference

12 December 2020

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

1 reference

12 December 2020

5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation

1 reference

12 December 2020

5-HT1-like receptor agonists and the pathophysiology of migraine

1 reference

12 December 2020

How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence

1 reference

12 December 2020

Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration

1 reference

12 December 2020

Treatment of Acute Migraine With Subcutaneous Sumatriptan

1 reference

12 December 2020

Pharmacological analysis of the haemodynamic effects of 5-HT1B/D receptor agonists in the normotensive rat

1 reference

12 December 2020

Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study

1 reference

12 December 2020

Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?

1 reference

12 December 2020

Assessment of Peripheral Vascular Effects of Antimigraine Drugs in Humans

1 reference

12 December 2020

Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types

1 reference

12 December 2020

Methodology of clinical trials of sumatriptan in migraine and cluster headache

1 reference

12 December 2020

Porcine carotid vascular effects of eletriptan (UK-116,044): a new 5-HT1B/1D receptor agonist with anti-migraine activity

1 reference

12 December 2020

Twenty-four-hour effectiveness of BMS 180048 in the acute treatment of migraine headaches

1 reference

12 December 2020

A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine

1 reference

12 December 2020

Oral sumatriptan compared with placebo in the acute treatment of migraine

1 reference

12 December 2020

Sumatriptan. An updated review of its use in migraine

1 reference

12 December 2020

Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group

1 reference

12 December 2020

5-HT receptors mediating contractions of the isolated human coronary artery

1 reference

12 December 2020

Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group

1 reference

12 December 2020

The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group

1 reference

12 December 2020

Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study

1 reference

12 December 2020

Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group

1 reference

12 December 2020

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

1 reference

12 December 2020

5-HT1-like receptors: a time to bid goodbye

1 reference

12 December 2020

Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy

1 reference

12 December 2020

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group

1 reference

12 December 2020

Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine

1 reference

12 December 2020

Oral sumatriptan in acute migraine

1 reference

12 December 2020

5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519

1 reference

12 December 2020

The pharmacology of the novel 5-HT1-like receptor agonist, GR43175.

1 reference

12 December 2020

Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats.

1 reference

12 December 2020

Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine

1 reference

12 December 2020

Rizatriptan: a new 5-HT1B/1D receptor agonist for the treatment of migraine

1 reference

12 December 2020

Coronary side-effect potential of current and prospective antimigraine drugs

1 reference

12 December 2020

Mode of action of the anti-migraine drug sumatriptan

1 reference

12 December 2020

Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine.

1 reference

12 December 2020

The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine

1 reference

12 December 2020

Treatment of migraine with BMS180048: response at 2 hours. North American BMS180048 Study Group

1 reference

12 December 2020

Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine

1 reference

12 December 2020

Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group

1 reference

12 December 2020

311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study

1 reference

12 December 2020

Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine

1 reference

12 December 2020

Recombinant saphenous vein 5-HT1B receptors of the rabbit: comparative pharmacology with human 5-HT1B receptors

1 reference

12 December 2020

Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences

1 reference

12 December 2020

A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group

1 reference

12 December 2020

Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytry

1 reference

12 December 2020

Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group.

1 reference

12 December 2020

Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers

1 reference

12 December 2020

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group

1 reference

12 December 2020

Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMA

1 reference

12 December 2020

The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve

1 reference

12 December 2020

Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine

1 reference

12 December 2020

Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths

1 reference

12 December 2020

Zolmitriptan: a new acute treatment for migraine

1 reference

12 December 2020

Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group

1 reference

12 December 2020

Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors

1 reference

12 December 2020

Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Subcutaneous Alniditan Study Group.

1 reference

12 December 2020

Sumatriptan--an oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group

1 reference

12 December 2020

Comparison of the cardiovascular effects of the novel 5-HT(1B/1D) receptor agonist, SB 209509 (VML251), and sumatriptan in dogs

1 reference

12 December 2020

Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. French Migraine Network Bordeaux-Lyon-Grenoble

1 reference

12 December 2020

Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine

1 reference

12 December 2020

Clinical and experimental effects of sumatriptan in humans

1 reference

12 December 2020

Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups

1 reference

12 December 2020

Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group

1 reference

12 December 2020

The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache

1 reference

12 December 2020

Blockade of porcine carotid vascular response to sumatriptan by GR 127935, a selective 5-HT1D receptor antagonist

1 reference

12 December 2020

The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers

1 reference

12 December 2020

Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan

1 reference

12 December 2020

A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine

1 reference

12 December 2020

Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses

1 reference

12 December 2020

Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats

1 reference

12 December 2020

Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache

1 reference

12 December 2020

Verbal scales in the acute treatment of migraine: semantic categories and clinical relevance.

1 reference

12 December 2020

The mode of action of sumatriptan is vascular? A debate

1 reference

12 December 2020

Sumatriptan suppositories for the acute treatment of migraine. S2B351 Study Group.

1 reference

12 December 2020

The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.

1 reference

12 December 2020

Efficacy of subcutaneous sumatriptan in repeated episodes of migraine

1 reference

12 December 2020

10.2165/00003495-200060060-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1020090057

0 references

1 reference